Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06574646
NA

Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+

Sponsor: The Eye Associates

View on ClinicalTrials.gov

Summary

Phase 1 will be ambispective, multi-site, single arm study in age-related cataract patients with regular astigmatism, who were bilaterally treated with the LAL+ IOLs Phase 2 will be a prospective, randomized, unmasked, comparative, multi-site study with 90 days of follow up. Subjects will be randomized in a 1:1 manner to LAL+ or Clareon VIvity Toric IOLs.

Key Details

Gender

All

Age Range

45 Years - Any

Study Type

INTERVENTIONAL

Enrollment

250

Start Date

2024-10-15

Completion Date

2026-08-01

Last Updated

2024-08-28

Healthy Volunteers

No

Conditions

Interventions

DEVICE

LAL+

LAL+ IOL allows for refractive error (both sphere and cylinder) enhancements post-IOL implantation by exposing the IOL to ultraviolet (UV) light through a series of noninvasive treatments with a Light Delivery Device.

DEVICE

Clareon Vivity Toric IOL

Clareon Vivity Toric IOL utilizes an extended depth of focus (EDOF) design, which incorporates nondiffractive wavefront shaping (X-WAVE) technology.

Locations (1)

The Eye Associates of Manatee, LLP

Bradenton, Florida, United States